Table 1.
Characteristics of the 41 patients with PsA and obesity included in the study
| Number (%) or median (IQR) | |
|---|---|
| Sex women/men, n (%) | 26 (63.4)/15 (36.6) |
| Age, years | 54 (48.5–62) |
| Duration of psoriasis, years | 32 (19–40) |
| Duration of PsA symptoms, years | 17 (11–27) |
| PsA type, n (%) | |
| Peripheral disease | 35 (85) |
| Axial disease | 2 (5) |
| Combination peripheral/axial | 4 (10) |
| History of dactylitis, n (%) | 21 (51) |
| History of anterior uveitis, n (%) | 3 (7) |
| NSAIDs, n (%) | 27 (66) |
| TNFi all, n (%) | 15 (37) |
| TNFi in monotherapy | 4 |
| TNFi + csDMARD | 11 |
| Ustekinumab monotherapy, n (%) | 1 (2.4) |
| csDMARD without biologic, n (%) | 19 (46) |
| Methotrexate | 13 |
| Sulfasalazine | 2 |
| Apremilast | 1 |
| Methotrexate + sulfasalazine | 3 |
| Anti-hypertensives, n (%) | 18 (44) |
| Lipid lowering therapy, n (%) | 6 (15) |
| Oral anti-diabetics, n (%) | 1 (2.4) |
csDMARD conventional synthetic disease modifying anti-rheumatic drug, NSAID non-steroidal anti-inflammatory drug, TNFi tumour necrosis factor inhibitor